Valion Bio (VBIO) Research & Development (2021 - 2025)

Valion Bio has reported Research & Development for 5 years, with the latest figure at $858000.0 in Q3 2025.

• On a quarterly basis, Research & Development rose 103.32% year-over-year to $858000.0 in Q3 2025; TTM through Sep 2025 was $2.2 million, a 11.05% increase from a year earlier, with the FY2024 full-year figure at $1.3 million, down 38.21% from the prior year.
• Research & Development was $858000.0 for Q3 2025 at Valion Bio, up from $655000.0 in the prior quarter.
• The five-year high for Research & Development was $1.1 million in Q2 2022, with the low at $300000.0 in Q1 2021.
• Average Research & Development over 5 years is $535105.3, with a median of $487000.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 226.09% in 2022, then tumbled 58.4% in 2023.
• Over 5 years, Research & Development stood at $692000.0 in 2021, then fell by 27.6% to $501000.0 in 2022, then surged by 46.71% to $735000.0 in 2023, then tumbled by 54.69% to $333000.0 in 2024, then jumped by 157.66% to $858000.0 in 2025.
• The last three Research & Development figures came in at $858000.0 (Q3 2025), $655000.0 (Q2 2025), and $335000.0 (Q1 2025), per Business Quant data.